Pfizer

US-based drugmaker Pfizer has purchased a minority equity interest and received an exclusive option to acquire the remaining equity in a Dutch biopharmaceutical firm, AM-Pharma.

AM-Pharma is involved in the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, AM-Pharma has received an upfront payment of $87.5m from Pfizer for the minority equity interest and exclusive option.

The deal will also include additional potential payments of up to $512.5m upon option exercise and potential launch of any product that may result from this agreement.

"This deal not only provides good shareholder value, but provides the next step in the development of recAP as a potential treatment for patients with acute kidney injury and other inflammatory diseases."

Pfizer worldwide research and development president Dr Mikael Dolsten said: "Clinical data for recAP show the potential to uniquely address acute kidney injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients."

Pfizer will be eligible to exercise option, after the completion of a Phase II trial of recAP in the treatment of acute kidney injury (AKI) related to sepsis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Pfizer, there are no drugs currently approved for AKI condition and the only treatment option is dialysis and supportive care and Phase II trial results are expected to be released in the second half of 2016.

See Also:

AM-Pharma is also developing recAP as a treatment for ulcerative colitis (UC) and hypophosphatasia (HPP).

AM-Pharma CEO Erik van den Berg said: "This deal not only provides good shareholder value, but provides the next step in the development of recAP as a potential treatment for patients with acute kidney injury and other inflammatory diseases."

Image: Pfizer world headquarters. Photo: courtesy of Jim.henderson.